Please ensure Javascript is enabled for purposes of website accessibility

Why the Aurora Cannabis-UFC Partnership Is a Huge Deal

By Andrew Button - May 29, 2019 at 7:27PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

There could be long-term rewards for the marijuana grower.

It's been a tough few months for Aurora Cannabis (ACB -38.46%) investors. After hitting a high point in April, the stock has been on a gradual but noticeable downtrend, following the company's most recent earnings report that showed high growth but missed analyst expectations. Although the company's sales jumped 20% quarter over quarter, its net loss was $150 million, showing the company is still a ways off from profitability.

Not all news from Aurora lately has been bad, however. In addition to growing its sales, the company has been working on acquisitions and partnerships to diversify its product offerings. One of the company's most interesting partnerships is with mixed-martial-arts (MMA) league Ultimate Fighting Championship or UFC, whose athletes are well known for endorsing sporting supplements. (UFC is owned by the Endeavor Group, which is planning an initial public offering.)

The deal in question is purported to be a research collaboration, where Aurora and the UFC's sports performance team will work together to see whether cannabidiol (CBD) products have any benefit to MMA fighters. However, the potential for new performance-enhancing products is not the only benefit that could come from this.

Bottles on a rock next to marijuana leaves.

Image source: Getty Images

Increased visibility

One obvious benefit that could come from Aurora's UFC partnership is visibility. In a crowded market, having a recognizable brand helps you stand out, and if the success of Nike teaches us anything, it's that hitching yourself to athletics can help with that.

Although Aurora's partnership with the UFC is presently focused on research, it's possible that a number of branding benefits could come as a result, such as Aurora having its name mentioned on air during UFC broadcasts or branded Aurora products having UFC fighter endorsements.

Research outcomes

Of course, the intended outcome of the Aurora-UFC partnership is to find applications for hemp-derived CBD oil or other products in sports medicine. Preliminary research has shown that CBD may be cardioprotective, meaning it helps strengthen the heart, and should this be proven conclusively, it would have obvious implications for sports medicine.

Other areas where CBD is being researched include depression and anxiety, two conditions that may have a bearing on athletic performance as well. Assuming that Aurora's research with the UFC sports medicine team is conclusive, it could result in patent-protected products that take off in the world of sports health.

Focus on high-margin product categories

One major benefit of Aurora's research with the UFC is that it is focused on high-margin products. For cannabis growers, two product areas are most profitable: CBD products and pre-rolled joints. By contrast, raw cannabis flower is comparatively cheap and low margin. Since Aurora's partnership with the UFC is focused on CBD, any resultant products would be sold in one of the higher-margin cannabis market segments and could prove profitable for Aurora if they take off.

This could be a major boon to the company, which is struggling to achieve consistent profits despite soaring revenue.

A version of this article originally appeared on The Motley Fool Canada site. For more coverage like this head to

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Aurora Cannabis Stock Quote
Aurora Cannabis
$1.68 (-38.46%) $-1.05

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.